LivaNova PLC

Valuation Analysis

About the Company

LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, Denmark, and internationally. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannulae, and other related accessories, as well as services related products. The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to ass

LivaNova PLC Stock at a Glance

LivaNova PLC (LIVN) is currently trading at $79.39 with a market capitalization of $4.4B. The trailing P/E ratio stands at 40.51x, with a forward P/E of 17.14x. The 52-week range spans from $41.02 to $80.73; the current price is 1.7% below the yearly high. Year-over-year revenue growth stands at +14.3%. The net profit margin stands at 7.47%.

💰 Dividend

LivaNova PLC currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Analyst Rating

10 analysts rate LivaNova PLC (LIVN) on consensus: Buy. The average price target is $80.60, implying +1.52% from the current price. Analyst price targets range from $67.00 to $95.00.

LivaNova PLC: The Investment Case in Detail

LivaNova PLC (LIVN) operates in the Healthcare — specifically Medical Devices — and is headquartered in United Kingdom. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

Revenue is growing at a healthy 14.3% pace year-over-year, suggesting the business model continues to find new customers and pricing power. With a gross margin near 67.86%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns.

The Bear Case

Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.

Valuation in Context

With a PEG ratio of 0.91, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity.

What to Watch Next

• The forward P/E of 17.14x is meaningfully below the trailing 40.51x — analysts expect earnings to step up; the next earnings release is the test.
• The share is trading at 96.6% of its 52-week range — a break above the recent high opens technical upside, a failure here often invites profit-taking.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Risk Profile

The data points to relatively defensive market behavior, elevated short interest (6.99%).

Trading Data

Related Stocks in the Same Sector

Where can I buy LivaNova PLC?

Compare top-rated brokers — low fees, trusted providers, fully regulated.